04 September 2018
A new report by visiongain predicts that drugs to treat retinal disorders will remain the leading ophthalmic drug submarket to 2026. This forecast and others appear in Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs, published in July 2016. Visiongain is a business information provider based in London, UK.
Ophthalmic Drugs Market Forecast 2016-2026 report examines the current and future trends for submarkets and companies in the ophthalmic drugs market.
In 2013, the World Health Organization (WHO) estimated the number of people with visual impairment at 285 million, of which 39 million were blind and 246 million had low vision. Blindness and visual impairment disproportionately affect older people; for example, 82% of all blind people are aged 50 years or older. This means that with a burgeoning elderly population globally, the number of people affected by visual impairment is set to increase rapidly.
The ophthalmic drugs market consists of those pharmaceuticals – both prescription and over-the-counter or OTC – which address the diseases and eye conditions that lead to visual impairment, as well as eye conditions of importance for other reasons. There is also a greater impact of eye disease in developing countries including the emerging markets of China and India. This makes understanding the ophthalmic drugs market, the leading companies in the market and the opportunities available is crucial for all those in fields related to the sector.
In this report, we examine are the sales of a wide range of ophthalmic drugs in the following submarkets: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs and Dry Eye Drugs. An analysis of 25 major drugs, with 10-year forecasts and upcoming pipeline candidates in the sector are also included for all of the major submarkets, along with analysis and forecasts for all major submarkets in the ophthalmic drugs market.
Current leading players in the ophthalmic drugs market are also analysed, with 10-year ophthalmic drug revenue forecasts. Also given is a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with analysis of news that may influence the course of the company. Analyses of promising pipeline candidates which may enter the market over the forecast period are also included.
Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: The ophthalmic drugs market remains an attractive niche market for pharmaceutical companies despite the level of generic competition that has been faced by a number of leading products in the market over the past few years. Although generic competition has reduced revenue for a number of products, the market has experienced growth across most segments, with a high level of both M&A and R&D activity to bring products to the market for various ophthalmic indications. The ageing global population will lead to an increasing prevalence of ophthalmic conditions, many of which are associated with old age, contributing to the growth that will be seen over the next 10 years. The rise of novel therapies such as RNA interference technologies, gene therapies and combination drug/device products will couple with improving support for reimbursement in the ophthalmic drug market will also drive growth across the forecast period. However difficulties with patient adherence and the rising cost of R&D may hinder growth within this market.”
Visiongain’s report provides revenue forecasts to 2026 for the ophthalmic drugs market and its leading submarkets, drugs and companies. The report discusses leading companies which hold significant shares of the market in depth. These companies include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer and Senju. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.
Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.
18 January 2022
The desire for various types of medications to assist combat a growing number of chronic diseases & lifestyle-related ailments is fuelling the overall deep freeze packaging logistics market demand.
14 January 2022
With COVID-19 pandemic, the prefilled syringes business has witnessed a significant growth. Since the outbreak of the pandemic, global market players involved in the development of the prefilled syringes market across the globe have increased their investment in raw materials and resources owing to the rise in demand for home based healthcare services.
11 January 2022
To promote their organic revenue growth and market presence, the top companies are pursuing different strategic initiatives such as OEM collaborations and new product development with better technological intricacy.